Abstract
Timely treatment of age-related macular degeneration (AMD) is integral in improving outcomes. To catch choroidal neovascularization as soon as possible, patients should monitor vision at home. The objective of this study is to explore the Hyperacuity App (HAC) as a screen for progression of disease in AMD. A cross-sectional, single-center study was performed with 33 subjects. Consent was obtained and patient information was protected in accordance with the protocol approved by the Yale Human Research Protection Program. A masked retinal subspecialist then graded the spectral-domain optical coherence tomography (SD-OCT) taken the same day to determine which patients required treatment. Further data about the patient were obtained through chart review. The HAC was shown to have 92.3% sensitivity and 61.5% specificity in distinguishing between patients who required treatment and those who did not require treatment. The HAC is a potential screen for choroidal neovascularization in AMD. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:708-715.].
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
